FDA Approves Pfizer’s Lipitor® to Reduce Risk of Strokes and Heart Attacks in Pa

Patients on Lipitor experienced 50% fewer strokes thean those on placebo.

Pfizer Inc announced that the U.S. Food and Drug Administration has approved its cholesterol- lowering medicine Lipitor(R) (atorvastatin calcium) to reduce the risk of stroke and heart attack in people with type 2 diabetes without evidence of heart disease but with other risk factors. Lipitor also received approval to reduce the risk of stroke in people without evidence of heart disease but with multiple risk factors other than diabetes. Common risk factors for heart disease include high cholesterol, high blood pressure, family history, age over 55, smoking, diabetes and obesity.

The FDA’s decision was based on the findings of the Collaborative Atorvastatin Diabetes Study (CARDS), a landmark trial of more than 2,800 patients with type 2 diabetes, near normal cholesterol, and at least one other risk factor, such as high blood pressure or smoking, that showed patients on Lipitor experienced nearly 50 percent fewer strokes than those on placebo. The CARDS trial was stopped nearly two years earlier than planned by the study’s Steering Committee because of the strong benefits among patients who took Lipitor.

The additional approval of Lipitor to reduce the risk of stroke in patients with multiple risk factors reflects findings from The Anglo- Scandinavian Cardiac Outcomes Trial: Lipid-Lowering Arm (ASCOT-LLA) another landmark trial which was also halted nearly two years earlier than planned. The trial found that Lipitor reduced the relative risk of stroke by 26% percent compared to placebo. The study involved more than 10,300 people with normal or borderline cholesterol and no prior history of heart disease, but with controlled high blood pressure and at least three other risk factors for heart disease, such as family history, age over 55, smoking, diabetes and obesity.

"Patients with multiple risk factors, including diabetes, face a greater threat of heart attack and stroke, so reducing their risk is critical," said David Waters, M.D., F.A.C.C., Chief of Cardiology, San Francisco General Hospital, San Francisco, CA. "The idea that we can reduce the risk of heart attack and stroke even in this high-risk population with a drug like Lipitor is important."
The American Heart Association (AHA) estimates that 700,000 Americans — or one person every 45 seconds — will experience a stroke in 2005. Stroke is more prevalent in adults age 65 and older, and the incidence of stroke continues to rise as age increases. According to the AHA, stroke is a leading cause of major disability in the United States. Direct (medical) and indirect (disability) costs related to stroke are anticipated at $57 billion in 2005.

The 2004 update to guidelines issued by the National Cholesterol Education Program confirms the added benefit of prescribing cholesterol-lowering medication like Lipitor, along with diet modification and exercise, to patients at risk for cardiovascular disease.

More than 18 million Americans suffer from diabetes, which is a leading risk factor for cardiovascular disease. The majority of people with diabetes — roughly 65 percent — will suffer a heart attack or stroke, a rate that is up to four times higher than in adults without diabetes. According to the American Diabetes Association recommended treatment guidelines, adults with type2 diabetes should be considered for statin therapy regardless of their LDL levels.
News release from Pfizer, September 29, 2005

================================

DID YOU KNOW:
There is Insufficient Evidence For Use Of Metformin As Treatment Of Overweight Or Obese Adults: This systematic review finds insufficient evidence to support the use of metformin, a drug used for the treatment of type 2 diabetes and polycystic ovary syndrome, as treatment of overweight or obese adults who do not have diabetes or polycystic ovary syndrome. Annals of Family Medicine https://www.annfammed.org.

PLEASE CLICK HERE TO UPDATE YOUR PROFILE!!!
https://www.diabetesincontrol.com/surveys/index.php